Êü¼ÍÀþÍøÍѵ»½Ñ¥Ç¡¼¥¿¥Ù¡¼¥¹¤Î¥á¥¤¥ó¥Ú¡¼¥¸¤Ø

ºîÀ®¡§ 2004/09/13 ÀµÌڱѰì

¥Ç¡¼¥¿Èֹ桡¡¡¡¡¡§030266
¥¦¥¤¥ë¥à¥¹¼ðáç¤ÎÊü¼ÍÀþ¼£ÎÅ
ÌÜŪ¡¡¡¡¡¡¡¡¡¡¡¡¡§¾®»ù¥¦¥¤¥ë¥à¥¹¼ðáç¤ËÂФ¹¤ëÊü¼ÍÀþÎÅË¡¤Î°ÕµÁ¤Ë¤Ä¤¤¤Æ¤Î¾Ò²ð
Êü¼ÍÀþ¤Î¼ïÊÌ¡¡¡¡¡§¥¨¥Ã¥¯¥¹Àþ
Êü¼ÍÀþ¸»¡¡¡¡¡¡¡¡¡§Ä¶¹â°µXÀþȯÀ¸ÁõÃÖ¡ÊÊü¼ÍÀþ¼£ÎÅÁõÃÖ¡Ë
ÀþÎÌ¡ÊΨ¡Ë¡¡¡¡¡¡¡§200-250cGy/min
±þÍÑʬÌî¡¡¡¡¡¡¡¡¡§°å³Ø¡¢Êü¼ÍÀþ¼£ÎÅ

³µÍס¡¡¡¡¡¡¡¡¡¡¡¡§
¥¦¥¤¥ë¥à¥¹¼ðáç¤Ï¥¢¥á¥ê¥«¤Ë¤ª¤±¤ëNational Wilms' Tumor Study(NWTS)¤Îrandomized trial¤Ë¤è¤ê¼£Ìþ¤Ç¤­¤ë¾®»ù¼ðáç¤È¤Ê¤Ã¤¿¡£Êü¼ÍÀþ¼£ÎŤϲ½³ØÎÅË¡¡¢¼ê½ÑÎÅË¡¤ÈÊ»¤»¤Æ¹Ô¤ï¤ì¤ë½¸³ØŪ¼£ÎŤÎÃæ¤ÇÀþÎÌ·Ú¸º¤¬¹Ô¤ï¤ì¤ÆÍè¤Æ¤ª¤ê¡¢¤Û¤È¤ó¤ÉÊü¼ÍÀþÈÕ´ü¹çÊ»¾É¤òÌäÂê¤Ë¤·¤Ê¤¯¤ÆºÑ¤à¤è¤¦¤Ë¤Ê¤Ã¤Æ¤­¤¿¡£

¾ÜºÙÀâÌÀ¡¡¡¡¡¡¡¡¡§
£±¡Ë¤Ï¤¸¤á¤Ë
¥¦¥¤¥ë¥à¥¹¼ðáç¤Ïǯ´ÖÌó50¡Á80Î㤬¾®»ù¤¬¤óÁ´¹ñÅÐÏ¿¤ËÊó¹ð¤µ¤ì¤Æ¤¤¤ë¡£National Wilms' Tumor Study(NWTS)¤Îrandomized trial¤Ë¤è¤ê¡¢¸½ºß¤Ç¤Ï¼£Ìþ¤Ç¤­¤¦¤ë¤â¤Î¤È¤Ê¤Ã¤¿¡£²½³ØÎÅË¡¤Î¶¯²½¤È¤È¤â¤Ë¡¢Êü¼ÍÀþ¼£ÎÅÀþÎ̤ϸºÎ̤µ¤ì¡¢¤Û¤È¤ó¤É¹çÊ»¾É¤òÌäÂê¤Ë¤·¤Ê¤¯¤Æ¤¹¤à¤è¤¦¤Ë¤Ê¤Ã¤¿¡£
¡¡
£²¡Ë¾®»ù¿Õ¼ðáçʬÎà
1. Low risk¡¡¡¡¡¡¡¡¡¡¡¡ mesoblastic nephroma
2. Intermediate risk¡¡¡¡Wilms' tumor
3. High risk¡¡¡¡¡¡¡¡¡¡¡¡focal anaplasia and diffuse anaplasiaClear cell
¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡sarcoma of the kidney¡ÊCCSK¡Ë
¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡Rhabdoid Tumor of the Kidney
¡¡
°Ê¾å¤ÎÆâmesoblastic nephroma¤ò½ü¤¯¿Õ¼ðáç¤òNWTS¤ª¤è¤ÓÆüËÜ¥¦¥¤¥ë¥à¥¹¼ðá祰¥ë¡¼¥×¥¹¥¿¥Ç¥£¡ÊJWiTS¡Ë¤Ç¼è¤ê°·¤¦¡¥
¡¡
£³¡ËÉ´üʬÎà(stage)
¹ñºÝŪ¤Ë¤ÏNWTSÉ´üʬÎà¡Êɽ1¡Ë¤¬ÍѤ¤¤é¤ì¤Æ¤¤¤ë¡£

ɽ1¡¡¥¦¥¤¥ë¥à¥¹¼ðáçÎ×¾²É´üʬÎà(NWTS)¡Ê¸¶ÏÀʸ1¤è¤ê°úÍÑ¡Ë
stage­µ¡§ ¼ðáç¤Ï¿Õ¤Ë¸Â¶É¤·¡¤´°Á´Å¦½Ð¤Ç¤­¤¿¤â¤Î¡¥¿ÕÈéËìɽÌ̤ÏÈȤµ¤ì¤Ê¤¤¡¤¼ðáçÇËÎö¤Ê¤·¡¤ÀÚ½üÃÇü¤ò±Û¤¨¤Æ¤¢¤­¤é¤«¤Ê»Ä¸¼ðáç¤Ê¤·¡¥
stage­¶¡§ ¼ðáç¤Ï¿Õ¤ò±Û¤¨¤Æ¤¤¤ë¤¬¡¤´°Á´Å¦½Ð¤Ç¤­¤¿¤â¤Î¡¥¼ðáç¤Î¸Â¶ÉÀ­¤Î¿ÊŸ¡¤·ì´É¿¯½±¡¤¼ðáçÀ¸¸¡¤¢¤ë¤¤¤Ï¦ʢÉô¤Ë¸Â¶É¤·¤¿¶É½ê¤Î¼ðáçϳ½Ð¤¢¤ê¡¥ÀÚ½üÃÇü¤¢¤ë¤¤¤Ï¤½¤ì¤ò±Û¤¨¤Æ¤¢¤­¤é¤«¤Ê»Ä¸¼ðáç¤Ê¤·¡¥
stage­·¡§ Ê¢Éô¤Ë¸Â¶É¤·¤¿Èó·ì¹ÔÀ­»Ä¸¼ðá礢¤ê¡¥¿ÕÌçÉô¡¤ËµÂçÆ°Ì®¤¢¤ë¤¤¤Ï¤½¤ì¤ò±Û¤¨¤ë¥ê¥ó¥ÑÀá¿»½á¤¢¤ê¡¥¼ðáçϳ½Ð¤Ë¤è¤ëÊ¢¹ÐÁ´ÂΤαøÀ÷¡¤¼ðáç¤ÎÊ¢¹ÐÇż¼ê½ÑÃÇü¤ò±Û¤¨¤Æ¸²Èù¶ÀŪ¤¢¤ë¤¤¤ÏÆù´ãŪ¤Ê¼ðáç¿ÊŸ¡¤½ÅÍ×ÁÈ¿¥¤Ø¤Î¶É½ê¿»½á¤Î¤¿¤á´°Á´ÀÚ½üÉÔǽ¡¥
stage­¸¡§ Stage­· °Ê¾å¤Îž°Ü¡ÊÎ㤨¤ÐÇÙ¡¤´Î¡¤¹ü¡¤Ç¾Å¾°Ü¡Ë
stage­¹¡§ ¿ÇÃÇ»þ¡¤Î¾Â¦À­¤Î¤â¤Î
£´¡Ë¼£ÎÅÊý¿Ë
NWTS¤Î½¾Íè¤Î¼£ÎÅÊý¿Ë¤Ï³°²Ê¼ê½Ñ¡Ê°ì´üŪÀÚ½ü¡Ë¤¬¼çÂΤǤ¢¤Ã¤¿¤Î¤ËÂФ·¤Æ¡¢ NWTS-5 ¤Ç¤ÏµðÂç¤Ê stage ­· ¾ÉÎã¤ËÂФ·¤ÆÀ¸¸¡¸å¤Î½ÑÁ°²½³ØÎÅË¡¡¢ÃÙ±ä°ì´üŪÀÚ½ü¤òǧ¤á¤ë¤è¤¦¤Ë¤Ê¤Ã¤¿¡£
JWiTS¤ÏNWTS-5¤ÈƱ¤¸¼£ÎÅË¡¤òºÎÍѤ·¡¢Í½¸åÎɹ¥·²¤Îstage ­·¡Á­¸¡¢Âà·ÁÀ®¼ðáç¤Îstage ­¶¡Á­¸¡¢¿ÕÌÀºÙ˦Æù¼ð¤ÎÁ´É´ü¡¢²£Ìæ¶ÚÆù¼ðÍͼðáç¤Îstage ­·¡Á­¸¤Ë½Ñ¸å¾È¼Í10.8 Gy/6²ó/8Æü¤¬É¬ÍפǤ¢¤ë¡£¼ê½ÑÆü¤ò½Ñ¸å0Æü¤È¤¹¤ë¤È¡¢²½³ØÎÅË¡¤Ï½Ñ¸å5Æü¤«¤é³«»Ï¤·¡¢½Ñ¸å¾È¼Í³«»Ï¤â½Ñ¸å9Æü¤è¤êÃÙ¤ì¤Æ¤Ï¤Ê¤é¤Ê¤¤¡£stage ­· ¤È¤Ê¤ë¤è¤¦¤ÊÊ¢¹ÐÁ´ÂΤμðáçϳ½Ð¤ä¼ðáçÇż郎ǧ¤á¤é¤ì¤¿¤È¤­¤Ï¡¢Á´Ê¢Éô¾È¼Í¤ò¹Ô¤¦¡£ ž°ÜÉÂÁã¤ËÂФ¹¤ëÊü¼ÍÀþ¼£ÎŤÏÍ­¸ú¤Ç¤¢¤ê¡¢²½³ØÎÅË¡¤ÈÊ»ÍѤȤʤ롣
¡¡
£µ¡Ë¼£ÎÅÊýË¡
£±¡¥ ɸŪÂÎÀÑ
GTV¡§¼ê½ÑÁ°¡Ê½é¿Ç»þ¡ËCT¤Ë¤Æǧ¤á¤é¤ì¤¿¸¶È¯Áã¡¢¥ê¥ó¥ÑÀáž°ÜÁã¡£
CTV¡§NWTS¤Ç¤Ï¸¶È¯¼ðáç¡¢¥ê¥ó¥ÑÀឰܤǤ¢¤ëGTV¤ò½¼Ê¬¤Ë´Þ¤ß¡¢³°Â¦¤Ï¦ʢÊɤò¾È¼ÍÌî¤ËÆþ¤ì¤ë¤³¤È¤È¤·¤Æ¤¤¤ë¡£¤Þ¤¿¼ðáç¤ÎƬ¦¡¢Èø¦¤Ï£±cm¤Î¥Þ¡¼¥¸¥ó¤ò¤È¤ë¤³¤È¤¬É¬ÍפǤ¢¤ë¡£Æ⦤ÏÂЦ˵ÂçÆ°Ì®¥ê¥ó¥ÑÀáÎΰè¤ò´Þ¤à¤è¤¦¤Ë¡¢ÄÇÂÎÁ´Éý¤¬¾È¼ÍÌî¤ËÆþ¤ë¤è¤¦¤ËÀßÄꤹ¤ë¡£
Ê¢¹ÐÁ´ÂΤμðáçϳ½Ð¤ä¼ðáçÇż郎ǧ¤á¤é¤ì¤¿¤È¤­¤Ï¡¢Á´Ê¢Éô¾È¼Í¡Ê²£³ÖËì¥É¡¼¥à¤«¤éÊĺ¿¹¦¤Þ¤Ç¡£ÂçÂܹüƬ¤Ï¼×ÊáˤȤ¹¤ë¡£
´Îž°Ü¤Ç¤Ï¡¢ÀÚ½üÉÔǽÎã¤Ë¤Ï£²cm¥Þ¡¼¥¸¥ó¤ò¤È¤ë¾È¼ÍÌî¤È¤¹¤ë¡£Â¿È¯´Îž°Ü¡¢ßÐÌ¡À­´Îž°Ü¤Î¾ì¹ç¡¢Á´´Î¤È¤¹¤ë¡£
¿ÇÃÇ»þ¤«¤éȽÌÀ¤·¤Æ¤¤¤ëÇÙž°Ü¤Ç¤ÏξÁ´ÇÙ¡¦ÇÙÀíÉô¤ÈÇÙÇØÉô²¼±ï¤ò´Þ¤ß¡¢Î¾¸ª¡Ê¾åÏÓ¹üƬ¡Ë¤ò¼×Ê乤뤳¤È¡£
PTV¡§CTV¤Ë¸ÆµÛ¤Ë¤è¤ëÊÑÆ°¤Ê¤É¤ò¹Íθ¤·ÀßÄꤹ¤ë¡£
½Ñ¸å¾È¼Í¤Ç¤¢¤ë¤Î¤Ç¡¢½Ñ¼Ô¤Î¸«²ò¤¬½ÅÍפǤ¢¤ë¡£¾®»ù¤ÎÊ¢Éô¾È¼Í¤Ç¤ÏÀÔÄǤؤαƶÁ¤ò¹Íθ¤·¡¢ÄÇÂÎÁ´Éý¤ò¾È¼ÍÌî¤ËÆþ¤ì¤ëÁ°¸åÆóÌç¾È¼Í¤¬´ðËܤǤ¢¤ë¡Ê¿Þ1¡Ë¡£


¿Þ1¡¡¥¦¥¤¥ë¥à¥¹¼ðá磳ºÐ½÷»ù Stage ­·¡ÊC1n1v1M0U0¡Ë¤Î½Ñ¸å¾È¼ÍÌ¥·¥ß¥å¥ì¡¼¥·¥ç¥ó¼Ì¿¿¡Ê¸¶ÏÀʸ1¤è¤ê°úÍÑ¡Ë

£²¡¥ ÀþÎÌ
ÁíÀþÎÌ10.8Gy¤È¤·¡¢£±ÆüÀþÎÌ1.8Gy¤Ç½µ£µÆü´Ö¾È¼Í¤ò¸¶Â§¤È¤¹¤ë¡£¾È¼ÍÌÁ´Ê¢¹Ð¾È¼Í¤Ê¤É¤ÈÂ礭¤¯¤Ê¤ë¤È¤­¤Ï¡¢£±ÆüÀþÎÌ1.5Gy¤È¤·¡¢ÁíÀþÎÌ10.5Gy¤È¤¹¤ë¡£¤·¤«¤·»Ä¸¼ðá礬Â礭¤¯¶É½êºÆȯ¤ò¤­¤¿¤¹²ÄǽÀ­¤Î¹â¤¤¤È¤­¤Ë¤Ï¡¢ÄɲþȼÍ10.8Gy¤ò¹Íθ¤¹¤ë¡£»Ä¸¿Õ¤Ï±ô¥Ö¥í¥Ã¥¯¤Ç¼×Ê乤뤫1/3°Ê¾å¤Ï14.4Gy¡¿£¸²ó¡¿10Æü¤ò±Û¤¨¤Ê¤¤¤è¤¦¤Ë¤·¡¢´Î¡¤Î1/2°Ê¾å¤Ï19.8Gy¡¿11²ó¡¿£²¡Á£³½µ¤ò±Û¤¨¤Ê¤¤¤è¤¦¤Ë¤¹¤ë¡£
´Îž°Ü¤Ç¤Ï¡¢ÀÚ½üÉÔǽÎã¤Ë¤Ï¶É½ê¾È¼Í¤È¤·¡¢Á´´Î¤¬¿¯¤µ¤ì¤Æ¤¤¤ì¤ÐÁ´´Î¾È¼Í19.8 Gy¡¿11²ó¡¿£²¡Á£³½µ¤È¤¹¤ë¡£¾È¼ÍÌî¤ò½Ì¾®¤·¤Æ5.4¡Á10.8Gy¡¿11²ó¡¿£²¡Á£³½µÄɲþȼͤ¹¤ë¤³¤È¤â¤¢¤ë¡£
ÇÙž°Ü¤Ç¤Ï¸¶Â§Åª¤ËξÁ´ÇÙ12Gy¡¿£¸²ó¡¿£²½µ¾È¼Í¤ò¹Ô¤¦¡£¾È¼Í½ªÎ»¸å2½µ´Ö¤¿¤Ã¤Æ¤â»Ä¸¤¹¤ë¾ì¹ç¤ÏÀÚ½ü¤¹¤ë¤«7.5Gy/5²óÄɲþȼͤò¹Íθ¤¹¤ë¡£18¥õ·î°Ê²¼¤ÎÆýÍÄ»ù¤ËÂФ·¤Æ¤Ï²½³ØÎÅË¡¤òÍѤ¤¡¢Êü¼ÍÀþ¼£ÎŤϹµ¤¨¤ë¡£Ã¢¤·¡¢¶»Éôñ½ã¼Ì¿¿¤ÇÇÙž°Ü¤¬Ç§¤á¤é¤ì¤º¡¢£Ã£Ô¤Ç¤Î¤ßǧ¤á¤é¤ì¤¿¤â¤Î¤ËÂФ·¤Æ¤Ï¡¢Á´ÇپȼͤÎŬ±þ¤Ç¤Ï¤Ê¤¤¡£
Ǿž°Ü¤Ç¤ÏÁ´Ç¾¤Ë30.6Gy¡¿17²ó¡¿£³¡Á£´½µ¾È¼Í¤·¡¢¹üž°Ü¶É½ê¤Ë¤â30.6Gy¡¿17²ó¡¿£³¡Á£´½µ¾È¼Í¤¹¤ë¡£
¡¡
£¶¡Ë¼£ÎÅÀ®ÀÓ
NWTS-4¡Êstage­¶¡Á­¸¡Ë¤Ç¤Ï¡¢pulse-intensive(sigle-dose) regimen¡Ê¥Ñ¥ë¥¹¶¯²½ÎÅË¡¡Ë¤Ë¤è¤ë2ǯ̵ÉÂÀ¸Â¸Î¨¤Ï89.4%¤Ç¤¢¤ê¡¢standard(divided-dose) regimen¡Êɸ½àÎÅË¡¡Ë¤Ë¤è¤ë90.5%¤ÈÊѤï¤ê¤¬¤Ê¤¯Îɤ¤À®ÀӤǤ¢¤ê¡¢¼£ÎÅ´ü´Ö¤Îû¤¤¥Ñ¥ë¥¹¶¯²½ÎÅË¡¤¬NWTS-£µ¤Îɸ½à¼£ÎŤȤʤäƤ¤¤ë¡£ÆüËܾ®»ù³°²Ê³Ø²ñ°­À­¼ðáç°Ñ°÷²ñ¤Î1986¡Á1990ǯÅÐÏ¿¾ÉÎã¤Îͽ¸åÄÉÀ×Ä´ºº¤Ç¤Ï¡¢Á´Îã¤Î5ǯÀ¸Â¸Î¨¤Ï84.7%¡¢É´ü­µ¡¢­¶¤Ç¤Ï91.9%¡¢É´ü­·80%¡¢É´ü­¹66.7%¡¢É´ü­¸18.1%¤Ç¤¢¤Ã¤¿¡£

¥³¥á¥ó¥È¡¡¡¡¡¡¡¡¡§
¾®»ù¼ðáç¤ÎȯÀ¸¿ô¤ÏÈó¾ï¤Ë¾¯¤Ê¤¯¡¢ËÜË®¤Ë¤ª¤¤¤Æ¤Ï¤½¤Îɸ½àŪ¤Ê¼£ÎÅË¡¤¬³ÎÄꤵ¤ì¤Æ¤¤¤Ê¤¤¡£¤½¤ÎÃæ¤Ç¥¦¥¤¥ë¥à¥¹¼ðáç¤Ï1969ǯ¤è¤ê¥¢¥á¥ê¥«¤Ë¤ª¤¤¤Ærandomized trial¤¬¹Ô¤ï¤ì¡¢Èó¾ï¤ËÎɹ¥¤Ê¼£ÎÅÀ®ÀÓ¤ò¾å¤²¤Æ¤­¤¿¡£¤³¤ì¤ò»²¹Í¤ËËÜË®¤Ë¤ª¤¤¤Æ¼£ÎŤ¬¹Ô¤ï¤ì¤Æ¤­¤¿¤¬¡¢ºÇ¶áNWTS¤Îµö²Ä¤Î¤â¤ÈNWTS-5¥×¥í¥È¥³¡¼¥ë¤½¤Î¤â¤Î¤òÆüËܤǤÎÅý°ì¥×¥í¥È¥³¡¼¥ë¤È¤·¤Æ¼£ÎŸ¦µæ¤¬³«»Ï¤µ¤ì¤¿¡£¤½¤Î¸¦µæ·ë²Ì¤ÎÀ®²Ì¤òÂÔ¤Á¤¿¤¤¡£

¸¶ÏÀʸ£± Data source 1¡§
¾®»ù¡¡­µ¡¥¥¦¥¤¥ë¥à¥¹¼ðáç
ÀµÌڱѰì
¹ñΩÀ®°é°åÎÅ¥»¥ó¥¿¡¼Êü¼ÍÀþ¿ÇÎÅÉô
Êü¼ÍÀþ¼£Îŷײ襬¥¤¥É¥é¥¤¥ó¡¡2004¡¢ÆüËÜÊü¼ÍÀþ²ÊÀìÌç°å²ñ¡¦°å²ñ¡¢ÆüËÜÊü¼ÍÀþ¼ðáç³Ø²ñ¡¢¡Ê¼Ò¡ËÆüËÜ°å³ØÊü¼ÍÀþ³Ø²ñÊÔ¡¥ÆüËÜÊü¼ÍÀþ²ÊÀìÌç°å²ñ¡¦°å²ñȯ¹Ô¡¡2004.7.1¡¢pp.171-175

»²¹Í»ñÎÁ£± Reference 1¡§
Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: a report from the National Wilms' Tumor Study Group¡¥
D.M. Green, N.E. Breslow, J.B. Beckwith, et al.
J. Clin. Oncol., 1998; 16: 237-45

»²¹Í»ñÎÁ£² Reference 2¡§
¾®»ù°­À­¸Ç·Á¼ðáç5¼ðáç¤Îͽ¸åÄ´ºº·ë²Ì¤ÎÊó¹ð¡Ý1986¡Á90ǯÅÐÏ¿¾ÉÎã¤Ë¤Ä¤¤¤Æ¡Ý.
ÆüËܾ®»ù³°²Ê³Ø²ñ°­À­¼ðáç°Ñ°÷²ñ
Æü¾®³°²ñ»ï¡¢1999; 35: 716-738

¥­¡¼¥ï¡¼¥É¡§¥¦¥¤¥ë¥à¥¹¼ðáç¡¢Êü¼ÍÀþ¼£ÎÅ¡¢Éû¿Õ¼ðáç¡¢¾®»ù¼ðáç¡¢Æù´ãŪ¼ðáçÍÆÀÑ¡¢Î×¾²ÅªÉ¸ÅªÍÆÀÑ¡¢·×²èŪɸŪÍÆÀÑ
Wilms' tumor, radiotherapy, adrenal tumor, pediatric tumor, GTV(gross tumor volume), CTV(clinical target volume), PTV(planning target volume)
ʬÎॳ¡¼¥É¡§030201,030602

Êü¼ÍÀþÍøÍѵ»½Ñ¥Ç¡¼¥¿¥Ù¡¼¥¹¤Î¥á¥¤¥ó¥Ú¡¼¥¸¤Ø